[1]陶 晋),刘亦武),方志伟),等.磁共振波谱分析CC/C值对去势抵抗性前列腺癌进展的预测价值[J].郑州大学学报(医学版),2019,(03):461-465.[doi:10.13705/j.issn.1671-6825.2018.10.126]
 TAO Jin),LIU Yiwu),FANG Zhiwei),et al.Prognostic assessment of magnetic resonance spectroscopy CC/C value for castration-resistant prostate cancer progression[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2019,(03):461-465.[doi:10.13705/j.issn.1671-6825.2018.10.126]
点击复制

磁共振波谱分析CC/C值对去势抵抗性前列腺癌进展的预测价值()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2019年03期
页码:
461-465
栏目:
应用研究
出版日期:
2019-05-20

文章信息/Info

Title:
Prognostic assessment of magnetic resonance spectroscopy CC/C value for castration-resistant prostate cancer progression
作者:
陶 晋1)刘亦武1)方志伟1)卢鸿雁2)魏晓松1)杨小明1)杨 阳1)易成智1)师 磊1)宋东奎1)
1)郑州大学第一附属医院泌尿外科 郑州 450052 2)华中科技大学附属同济医院泌尿外科 武汉 430000
Author(s):
TAO Jin1) LIU Yiwu1) FANG Zhiwei1) LU Hongyan2) WEI Xiaosong1) YANG Xiaoming1) YANG Yang1) YI Chengzhi1) SHI Lei1) SONG Dongkui1)
1)Department of Urology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052 2)Department of Urology, Tongji Hospital, Huazhong University of Science and Technology,Wuhan 430000
关键词:
前列腺肿瘤 内分泌治疗 磁共振波谱分析
Keywords:
prostatic neoplasm hormonal therapy magnetic resonance spectroscopy
分类号:
R737.2
DOI:
10.13705/j.issn.1671-6825.2018.10.126
摘要:
目的:探讨磁共振波谱分析(胆碱+肌酸)/枸橼酸盐比值(CC/C)对去势抵抗性前列腺癌(CRPC)进展的预测价值。方法:收集确诊为前列腺癌并接受最大限度雄激素阻断方案内分泌治疗的44例患者的资料,包括年龄、前列腺体积、CC/C、CRPC进展时间、Gleason评分、骨转移情况、前列腺特异性抗原(PSA)初始值等。结果:以中位CC/C值为截点将患者分为两组。两组患者的各项临床特征差异无统计学意义。Kaplan-Meier生存分析显示CC/C值较高的患者中位CRPC进展时间短于较低的患者(χ2=26.237,P<0.001)。Cox回归分析结果提示高CC/C值为CRPC进展的独立预测因素(RR=2.510,95%CI=1.812~3.476)。结论:磁共振波谱分析CC/C值可用于预测CRPC进展。
Abstract:
Aim:To explore the prognostic assessment of magnetic resonance spectroscopy(MRS)CC/C value for castration-resistant prostate cancer(CRPC)progression.Methods:A total of 44 patients with prostate cancer who received androgen deprivation therapy as the primary therapy were enrolled. The information such as age, prostate volume, CC/C value, CRPC progression time, Gleason score, bone metastasis, PSA at the initiation of therapy were collected.Results:All the patients were allocated into two groups by the median CC/C value,there were no significant differences in clinical characteristics between the two groups(P>0.05).Kaplan-Meier survival analysis showed that the medium CRPC progression time of the patients with high CC/C value was significantly shorter than those with low CC/C value(χ2=26.237,P<0.001). Cox analysis showed that high CC/C value was an independent prognostic factor for CRPC progression,and the risk was significantly increased in patients with high CC/C value(RR=2.510,95%CI=1.812-3.476).Conclusion:The CC/C value of magnetic resonance spectroscopy is a predictive factor of CRPC progression.

参考文献/References:

[1] SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics, 2017[J].CA Cancer J Clin,2017,67(1):7
[2] CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in China, 2015[J].CA Cancer J Clin,2016,66(2):115
[3] MOTTET N,BELLMUNT J,BOLLA M,et al.EAU guidelines on prostate cancer. Part Ⅱ: treatment of advanced, relapsing, and castration-resistant prostate cancer[J].Eur Urol,2011,59(4):572
[4] LOWRANCE WT,MURAD MH,OH WK,et al.Castration-resistant prostate cancer:AUA guideline amendment 2018[J].J Urol,2018,200(6):1264
[5] DURMUS T,BAUR A,HAMM B.Multiparametric magnetic resonance imaging in the detection of prostate cancer[J].Aktuelle Urol,2014,45(2):119
[6] ICARD P,LINCET H.The reduced concentration of citrate in cancer cells: an indicator of cancer aggressiveness and a possible therapeutic target[J].Drug Resist Updat,2016,29:47
[7] RAIS-BAHRAMI S,TURKBEY B,GRANT KB,et al.Role of multiparametric magnetic resonance imaging in the diagnosis of prostate cancer[J].Curr Urol Rep,2014,15(3):387
[8] PEYROMAURE M,DEBR? B,MAO K,et al.Management of prostate cancer in China: a multicenter report of 6 institutions[J].J Urol,2005,174(5):1794
[9] KATZENWADEL A,WOLF P.Androgen deprivation of prostate cancer:leading to a therapeutic dead end[J].Cancer Lett,2015,367(1):12
[10]COUTINHO I,DAY TK,TILLEY WD,et al.Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence[J].Endocr Relat Cancer,2016,23(12):T179
[11]CHANDRASEKAR T,YANG JC,GAO AC,et al.Mechanisms of resistance in castration-resistant prostate cancer(CRPC)[J].Transl Androl Urol,2015,4(3):365
[12]GLUNDE K,SHAH T,WINNARD PT,et al.Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model [J].Cancer Res,2008,68(1):172
[13]ASIM M,MASSIE CE,ORAFIDIYA FA,et al.Choline kinase alpha as an androgen receptor chaperone and prostate cancer therapeutic target[J].J Natl Cancer Inst,2016,108(5):371
[14]TEOH JY,TSU JH,YUEN SK,et al.Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen C velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy[J].Asian J Androl,2017,19(1):98
[15]纪光杰,黄聪,宋刚,等.去势抵抗性前列腺癌进展时间的预测因素分析[J].北京大学学报(医学版),2017,4(4):657
[16] HUANG SP,BAO BY,WU MT,et al.Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy[J].Aging Male,2012,15(1):34

相似文献/References:

[1]黄泓玮,孙永得,李建华,等.人前列腺癌组织中ALKBH3及VEGF-C蛋白的表达*[J].郑州大学学报(医学版),2016,(03):356.
 HUANG Hongwei,SUN Yongde,LI Jianhua,et al.Expressions of ALKBH3 and VEGF-C protein in human prostate cancer tissue[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2016,(03):356.

备注/Memo

备注/Memo:
【作者简介】宋东奎,通信作者,男,1963年7月生,博士,主任医师,研究方向:泌尿、男性生殖系统肿瘤,E-mail:dksong@zzu.edu.cn
更新日期/Last Update: 2019-05-20